United Therapeutics Corporation (OQ:UTHR)

Business Focus: Biotechnology & Medical Research

Feb 27, 2024 06:00 am ET
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston.
Feb 21, 2024 06:00 am ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022.
Feb 21, 2024 05:55 am ET
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement of litigation with the United States Food and Drug Administration (FDA). In the litigation, United Therapeutics alleges that the FDA mistakenly permitted Liquidia Corporation (Liquidia) to skirt longstanding FDA rules, precedents, and procedures on how pending drug approval applications are handled by the agency. In doing so, the FDA inappropriately denied United Therapeutics its right to obtain a stay of Liquidia’s final approval until United Therapeutics’ pending patent infringement claim aga
Feb 14, 2024 06:00 am ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.
Dec 29, 2023 06:00 am ET
United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
Dec 13, 2023 09:15 am ET
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s development-stage, fully-implantable manufactured kidney product known as m
Dec 12, 2023 06:00 am ET
United Therapeutics and Miromatrix Medical Announce Successful Tender Offer
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“Merger Sub”), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s development-stage, fully-implantable manufactured kidney product known as mirokidney™ by Decembe
Dec 07, 2023 06:00 am ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024
United Therapeutics (Nasdaq: UTHR), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2024. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awards was announced on December 6, 2023, is available on Newsweek’s
Nov 13, 2023 10:19 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eargo, Inc. (Nasdaq – EAR), Miromatrix Medical, Inc. (Nasdaq – MIRO), Physicians Realty Trust (NYSE – DOC), Spi
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Nov 01, 2023 06:00 am ET
United Therapeutics Corporation Reports Third Quarter 2023 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter of 2022.
Oct 31, 2023 06:05 am ET
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, which will evaluate nebulized Tyvaso® (treprostinil) Inhalation Solution in 698 adult patients with progressive pulmonary fibrosis (PPF). This is in addition to two separate ongoing registration-phase studies, TETON 1 and TETON 2, of nebulized Tyvaso in patients with another type of pulmonary fibrosis (PF) known as idiopathic pulmonary fibrosis (IPF).
Oct 31, 2023 06:00 am ET
United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the UBS Biopharma Conference 2023 in Miami Beach, Florida.
Oct 30, 2023 06:05 am ET
United Therapeutics to Acquire Miromatrix Medical
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of...
Oct 30, 2023 06:00 am ET
United Therapeutics to Acquire Miromatrix Medical
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix.
Oct 25, 2023 06:00 am ET
United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023.
Sep 22, 2023 02:15 pm ET
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart into a living person, and a 61-day study of the UThymoKidney™ xenokidney and thymus in a human pre-clinical model.
Sep 12, 2023 06:00 am ET
United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its 2023 Corporate Responsibility and Public Benefit Report covering its 2022 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of its patients and other stakeholders.
Sep 01, 2023 06:00 am ET
United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Morgan Stanley 21st Annual Global Healthcare Conference in New York City.
Aug 02, 2023 06:00 am ET
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022.
Jul 26, 2023 06:00 am ET
United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its second quarter 2023 financial results before the market opens on Wednesday, August 2, 2023.
Jul 24, 2023 11:45 am ET
United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc. The Federal Circuit affirmed that Liquidia’s proposed Yutrepia™ product infringes a United Therapeutics’ patent, U.S. Patent No. 10,716,793 (the ’793 patent). As a result, the U.S. Food and Drug Administration (FDA) cannot grant Liquidia final approval for its Yutrepia product until expiration
Jun 14, 2023 06:00 am ET
United Therapeutics Unveils Net Zero Energy Distribution Center
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, yesterday unveiled its new net zero energy distribution center located on the company’s co-headquarters campus in Research Triangle Park, North Carolina.
May 03, 2023 06:00 am ET
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022.
Apr 26, 2023 06:00 am ET
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023.
Apr 18, 2023 06:00 am ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 43rd Annual Meeting and Scientific Sessions in Denver, Colorado on April 19-22, 2023, and at the American Thoracic Society (ATS) International Conference in Washington, D.C. on May 19-24, 2023. At ATS, United Therapeutics will host an educational symposium on pulmonary hypertension associated with interstitial lung disease (P
Mar 06, 2023 04:30 pm ET
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 33rd Annual Healthcare Conference.
Feb 28, 2023 06:00 am ET
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43rd Annual Health Care Conference in Boston.
Feb 22, 2023 06:00 am ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2022.
Feb 15, 2023 06:00 am ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2022 financial results before the market opens on Wednesday, February 22, 2023.
Jan 02, 2023 06:00 am ET
United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the 41st annual J.P. Morgan Healthcare Conference in San Francisco.
Dec 08, 2022 06:00 am ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2023
United Therapeutics (Nasdaq: UTHR), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2023. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awards was announced on December 7, 2022, is available on Newsweek’s
Nov 02, 2022 06:00 am ET
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third quarter of 2021.
Nov 01, 2022 06:00 am ET
United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the Credit Suisse 31st Annual Healthcare Conference in Los Angeles.
Oct 31, 2022 06:00 am ET
United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that a preliminary analysis of the EXPEDITE study in patients suffering from World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) demonstrated that 79% of patients in the study achieved an Orenitram (treprostinil) extended-release tablet dose of at least 4 mg three times daily (TID), for a 12 mg total daily dose at 16 weeks, after an up to eight week induction treatment period with Remodulin (treprostinil) injection. Detailed study res
Oct 26, 2022 06:00 am ET
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022.
Oct 14, 2022 06:00 am ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that three presentations and two posters across its commercial and development portfolio will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians taking place October 16-19, 2022, in Nashville, Tennessee. In addition, United Therapeutics is sponsoring the CHEST Women & Pulmonary Luncheon and will host an educational symposium on pulmonary hypertension associated with interstitial lung disease (PH-ILD), both on Monday, October 17, 2022.
Oct 11, 2022 06:00 am ET
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary fibrosis (IPF) at sites outside the United States and Canada. This second registration study is part of the broader global TETON program evaluating Tyvaso for the treatment of IPF. The 52-week study will evaluate the impact of Tyvaso on a key prognostic indicator for IPF known as forced vital capacity (FVC). IPF is a progr
Sep 12, 2022 05:00 pm ET
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance (ESG) priorities. Contained within the report is the company’s inaugural public benefit report, detailing United Therapeutics’ efforts to meet its public benefit purpose: to provide a brighter future for patients through (a) the development of novel pharmaceutical ther
Sep 08, 2022 04:05 pm ET
3D Systems Announces Formation of New Biotech Company, Systemic Bio™, to Accelerate Drug Discovery and Development
Today, 3D Systems (NYSE:DDD) announced the formation of a new, wholly owned company called Systemic Bio™, a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development. Systemic...
Aug 31, 2022 06:40 pm ET
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics’ U.S. patents 9,593,066 (the ’066 patent) and 10,716,793 (the ’793 patent). This litigation concerns whether Liquidia Technologies, Inc.’s proposed treprostinil inhalation powder, YutrepiaTM, would infringe the ’066 and ’793 patents.
Aug 24, 2022 06:00 am ET
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented at the European Society of Cardiology (ESC) Congress 2022, taking place August 26-29, 2022, and the European Respiratory Society (ERS) International Congress 2022, taking place September 4-6, 2022. Both congresses will be held in Barcelona, Spain.
Aug 03, 2022 06:00 am ET
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.
Jul 27, 2022 06:00 am ET
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022.
Jun 06, 2022 06:00 am ET
United Therapeutics Provides an Update on Its Organ Printing Programs
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that in partnership with 3D Systems Corporation (NYSE: DDD) it has produced the world’s most complex 3D-printed object – a human lung scaffold – and demonstrated it at the LIFE ITSELF Conference that occurred May 31 to June 3, 20
Jun 03, 2022 04:30 pm ET
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Jefferies Healthcare Conference in New York City.
May 24, 2022 06:00 am ET
United Therapeutics Announces FDA Approval of Tyvaso DPI™
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD.
May 04, 2022 06:00 am ET
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew 22% year-over-year to $461.9 million, compared to $379.1 million in the first quarter of 2021.
Apr 29, 2022 06:00 am ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that eight posters and three mini-symposia across the company’s commercial and development portfolio will be presented at the 2022 American Thoracic Society (ATS) International Conference, taking place May 13-18, 2022, in San Francisco. In addition, the company is hosting a sponsored symposium on pulmonary hypertension associated with interstitial lung disease (PH-ILD) and is sponsoring the ATS 2022 Women’s Forum.
Apr 27, 2022 06:00 am ET
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022.
Apr 06, 2022 06:00 am ET
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) in the journal Pulmonary Circulation.
Mar 08, 2022 06:00 am ET
United Therapeutics Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 32nd Annual Healthcare Conference.
Mar 01, 2022 06:00 am ET
United Therapeutics Corporation to Present at the Cowen 42nd Annual Health Care Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 42nd Annual Health Care Conference.
Feb 24, 2022 06:00 am ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2021. Full year total revenues rose to $1,686 million, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2021.
Feb 21, 2022 06:00 am ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before the market opens on Thursday, February 24, 2022.
Jan 21, 2022 06:00 am ET
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
United Therapeutics Corporation (UT) (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, announced today that the world's first recipient of an investigational genetically-modified xenotransplanted organ, UT’s UHeart™, reached a two-week milestone. University of Maryland School of Medicine (UMSOM) surgeons report continued post-operative cardiovascular improvement in the patient with normal organ function. In addition, the first peer-reviewed publication of a similarly gene-edited investigational xenograft, UT’s UKidney™, in a hu
Dec 30, 2021 06:00 am ET
United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, and Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company’s business during a fireside chat conversation hosted by J.P. Morgan biotechnology analyst Jessica Fye.
Dec 03, 2021 06:00 am ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on December 2, 2021, available on Newsweek’s
Nov 03, 2021 06:00 am ET
United Therapeutics Corporation Reports Third Quarter 2021 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced its financial results for the quarter ended September 30, 2021. Total revenue in the third quarter of 2021 grew 17% year over year to $444.7 million, compared to $380.1 million in the third quarter of 2020.
Nov 01, 2021 06:00 am ET
United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Credit Suisse 30th Annual Healthcare Conference.
Oct 27, 2021 04:25 pm ET
3D Systems and United Therapeutics Announce Expansion of Bioprinting Program
3D Systems (NYSE:DDD) is pleased to announce an expansion of its joint development program with United Therapeutics Corporation (NASDAQ:UTHR). The development and license agreement, first established in 2017, combines the 3D printing expertise of...
Oct 27, 2021 06:00 am ET
United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2021 financial results before the market opens on Wednesday, November 3, 2021.
Oct 21, 2021 06:00 am ET
United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today detailed the new clinical and real-world evidence on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) presented at CHEST 2021, the annual meeting of the American College of Chest Physicians. United Therapeutics and its collaborators presented 10 abstracts across a broad range of studies in PAH and PH-ILD,
Oct 18, 2021 06:00 am ET
United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced an update on the U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) for Tyvaso DPI™, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), to improve exercise capacity. On Friday, October 15, 2021, the FDA issued a complete response declining to approve the NDA at this time. The FDA's letter noted only a single deficiency preventing app
Oct 11, 2021 06:00 am ET
United Therapeutics to Present New Data at CHEST Annual Meeting 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 11, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented as posters at CHEST 2021, the annual meeting of the American College of Chest Physicians, which will be held virtually October 17-20. United Therapeutics and its collaborators are presenting a total of 10 abstracts acr
Sep 30, 2021 04:30 pm ET
United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it has officially converted to a public benefit corporation (PBC). The conversion follows shareholder approval of the company's proposal to amend its charter at today's Special Meeting of Shareholders. This is the first PBC conversion of a public biotech or pharmaceutical company.
Sep 10, 2021 06:00 am ET
United Therapeutics Releases its Annual Corporate Responsibility Report
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its second annual Corporate Responsibility Report with 2020 highlights, providing stakeholders important information regarding the company's commitment to environmental, social, and governance (ESG) priorities. 
Sep 07, 2021 06:00 am ET
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today presented new clinical data from the BREEZE study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Congress 2021.
Aug 25, 2021 06:00 am ET
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it is joining forces with former NFL player Devon Still and his daughter Leah, a survivor of high-risk neuroblastoma, to launch the educational initiative "Braving NeuroBLASToma" shining a light on the rare cancer affecting immature nerve cells called neuroblasts.iv Neuroblastoma often develops in infants and children under the age of five, but the average age of diagnosis is between one and two years old.
Aug 24, 2021 06:00 am ET
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Congress 2021, which will be held virtually from September 5-8, 2021.
Aug 04, 2021 06:00 am ET
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the second quarter of 2021 grew 23% year over year to $446.5 million, compared to $362.0 million in the second quarter of 2020.
Aug 03, 2021 06:00 am ET
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 2021 Wedbush PacGrow Healthcare Virtual Conference.
Jul 28, 2021 06:00 am ET
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2021 financial results before the market opens on Wednesday, August 4, 2021.
Jun 30, 2021 06:00 am ET
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 30, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the publication in The Lancet Respiratory Medicine of a post-hoc analysis of forced vital capacity (FVC) change in patients during the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3 pulmonary hypertension).
Jun 16, 2021 10:59 am ET
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA
DANBURY, Conn., June 16, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA) accepted for priority review of the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The development marks the second compound formulated with MannKind's Technosphere® technology to be reviewed by the FDA, w
Jun 16, 2021 06:15 am ET
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA) accepted for priority review of the New Drug Application...
Jun 16, 2021 06:00 am ET
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 16, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency's review to be complete in October 2021. FDA also indicated that they have not identified any potential review issues at this t
Apr 19, 2021 06:00 am ET
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today in the development of Tyvaso DPI™ as United Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA)....
Feb 24, 2021 03:30 pm ET
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 41st annual Cowen Health Care Conference.
Feb 24, 2021 05:00 am ET
United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2020. Full year net revenue rose to $1,483 million, as U.S. patients being treated with the company's treprostinil-based therapies reached an all-time high during the fourth quarter.
Feb 17, 2021 05:00 am ET
United Therapeutics Corporation To Report Fourth Quarter And Full Year 2020 Financial Results Before The Market Opens On Wednesday, February 24, 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2020 financial results before the market opens on Wednesday, February 24, 2021.
Feb 10, 2021 05:00 am ET
United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin®
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity® Pump for Remodulin® for patients with pulmonary arterial hypertension (PAH).
Jan 28, 2021 05:00 am ET
United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that that the BREEZE study of Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients with pulmonary arterial hypertension (PAH) transitioning from Tyvaso (treprostinil) Inhalation Solution. In addition, a pharmacokinetic (PK) study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution.
Jan 27, 2021 08:30 am ET
3D Systems Announces Breakthrough in Bioprinting Technology and Expansion of Regenerative Medicine Initiative
3D Systems (NYSE:DDD) today announced its decision to significantly expand its development efforts focused on regenerative medicine and bioprinting solutions. This decision was driven by the tremendous progress made in collaboration with United...
Jan 13, 2021 04:01 pm ET
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study of Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the New England Journal of Medicine. Results from INCREASE, the largest and most comprehensive completed study of adult patients with PH-ILD, showed that treatment with inhaled Tyvaso was well tolerated and improved the exercise capaci
Jan 04, 2021 05:00 am ET
United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a presentation and question and answer session at the 39th annual J.P. Morgan Healthcare Conference.
Dec 28, 2020 09:00 am ET
Y-mAbs Announces Sale of Priority Review Voucher
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...
Dec 28, 2020 05:00 am ET
United Therapeutics Announces Agreement To Acquire Priority Review Voucher
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The PRV entitles the holder to designate an NDA for priority review and provides for an expedited eight-month review, instead of the standard twelve-month review period. Following the close of the transaction, United Therapeutics intends to apply the PRV
Dec 09, 2020 05:00 am ET
United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis (IPF). United Therapeutics intends to initiate a phase 3 study, called TETON, to evaluate the use of Tyvaso® (treprostinil) Inhalation Solution in patients with IPF. FDA recently cleared United Therapeutics' investigational new drug application (IND) for the TETON study, and th
Nov 24, 2020 05:00 am ET
United Therapeutics Releases Its First Corporate Responsibility Report
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its initial Corporate Responsibility Report with primarily 2019 data and selected 2020 highlights, providing stakeholders important information regarding the company's commitment to environmental, social, and governance (ESG) priorities. 
Nov 10, 2020 05:00 am ET
United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual London Healthcare Conference.
Nov 02, 2020 04:55 am ET
United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Credit Suisse 29th Annual Virtual Healthcare Conference.
Oct 28, 2020 06:00 am ET
United Therapeutics Corporation Reports Third Quarter 2020 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, 2020.
Oct 22, 2020 06:00 am ET
United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced new clinical data on Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) at CHEST 2020, the annual meeting of the American College of Chest Physicians, held October 18-21. The presentation featured safety data from the phase 3 INCREASE study of Tyvaso, which showed that patients with PH-ILD receiving Tyvaso, compared to those receiving placebo, experienced fewer exace
Oct 21, 2020 06:00 am ET
United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 financial results before the market opens on Wednesday, October 28, 2020.
Oct 15, 2020 06:00 am ET
United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present clinical trial data on Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) at CHEST 2020, the annual meeting of the American College of Chest Physicians, which will be held on October 18-21. The presentation will include data from the phase 3 INCREASE study of Tyvaso in patients with PH-ILD, which included an evaluation of the impact of Tyvaso on param
Aug 05, 2020 06:00 am ET
United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Wedbush PacGrow Healthcare Virtual Conference.
Jul 29, 2020 06:00 am ET
United Therapeutics Corporation Reports Second Quarter 2020 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 29, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2020.
Jul 23, 2020 06:00 am ET
United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 23, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the United States Patent and Trademark Office issued a new patent on July 21, 2020, relating to Tyvaso® (treprostinil) Inhalation Solution. The new patent, U.S. Patent No. 10,716,793, expires May 14, 2027, and is listed in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations publication, also known as the Orange Book, for Tyvaso.
Jul 22, 2020 06:00 am ET
United Therapeutics Corporation To Report Second Quarter 2020 Financial Results Before The Market Opens On Wednesday, July 29, 2020
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2020 financial results before the market opens on Wednesday, July 29, 2020.
Jun 17, 2020 06:00 am ET
United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at a Breaking News Session hosted by the American Thoracic Society (ATS) on June 24, 2020.
Jun 05, 2020 06:00 am ET
United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Liquidia Technologies, Inc. (Liquidia) for infringement of the following patents relating to United Therapeutics' product Tyvaso® (treprostinil) Inhalation Solution: U.S. Patent Nos. 9,604,901 (the '901 patent) and 9,593,066 (the '066 patent), both of which expire in December 2028.
May 26, 2020 06:00 am ET
United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Health Care Conference.
May 06, 2020 06:00 am ET
United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the BofA Securities Virtual Health Care Conference 2020.
Apr 29, 2020 06:00 am ET
United Therapeutics Corporation Reports First Quarter 2020 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 29, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2020. First quarter net revenue decreased 2% to $356.3 million year-over-year while first quarter net revenue excluding Adcirca increased 0.4%, compared to the first quarter of 2019. First quarter diluted earnings per share (EPS) was $3.12 compared to an $11.32 per share loss in the first quarter of 2019. Non-GAAP diluted EPS of $3.61 was up 1% from the first quarter of 2019.
Apr 23, 2020 06:00 am ET
United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertensio
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 23, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today detailed recent publications on Orenitram® (treprostinil) Extended-Release Tablets, which provide additional evidence of the beneficial treatment effect in patients with pulmonary arterial hypertension (PAH).
Apr 22, 2020 06:00 am ET
United Therapeutics Corporation to Report First Quarter 2020 Financial Results Before the Market Opens on Wednesday, April 29, 2020
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2020 financial results before the market opens on Wednesday, April 29, 2020.
Apr 09, 2020 11:00 am ET
Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome
WARREN, N.J., April 9, 2020 /PRNewswire/ -- Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS).
Oct 30, 2019 06:00 am ET
United Therapeutics Corporation Reports Third Quarter 2019 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, 2019.
Oct 23, 2019 06:00 am ET
United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2019 financial results before the market opens on Wednesday, October 30, 2019.
Oct 21, 2019 06:00 am ET
United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the New Drug Application for Orenitram® (treprostinil) Extended-Release Tablets reflecting data from the FREEDOM-EV study in patients with pulmonary arterial hypertension (PAH).  
Sep 11, 2019 06:00 am ET
United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020. Trevyent is a post-phase III development-stage drug-device combination product that combines two-day, single use, disposable PatchPump® technology with tr
Aug 19, 2019 04:35 pm ET
iBio Inks 3D Bioprinting Agreement
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen...
Aug 06, 2019 06:00 am ET
United Therapeutics Corporation To Present At 2019 Wedbush PacGrow Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 6, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 2019 Wedbush PacGrow Healthcare Conference in New York City.
Jul 31, 2019 06:00 am ET
United Therapeutics Corporation Reports Second Quarter 2019 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2019.
Jul 24, 2019 06:00 am ET
United Therapeutics Corporation To Report Second Quarter 2019 Financial Results Before The Market Opens On Wednesday, July 31, 2019
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2019 financial results before the market opens on Wednesday, July 31, 2019.
May 28, 2019 06:00 am ET
United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 28, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Jefferies 2019 Healthcare Conference in New York City.
May 07, 2019 06:00 am ET
United Therapeutics And DEKA Announce FDA Clearance Of The Unity Subcutaneous Delivery System For Remodulin®
RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., May 7, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of 510(k) clearance by the U.S. Food and Drug Administration (FDA) for the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also referred to as the RemUnity™ system.
May 01, 2019 06:00 am ET
United Therapeutics Corporation Reports First Quarter 2019 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 1, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2019.
Apr 29, 2019 06:00 am ET
United Therapeutics Announces FDA Approval Of XPS™ And Steen Solution™ Used To Perform Centralized Ex-Vivo Lung Perfusion Services
SILVER SPRING, Md., April 29, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that its collaborator, XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the products XPS™ and STEEN Solution™. This approval means that STEEN Solution, XPS and the accompanying single-use articles are the only medical device products that are approved in the United States for ex-vivo lung perfusion (EVLP) of initially unacceptable donated lungs at body temperature.
Apr 24, 2019 06:00 am ET
United Therapeutics Corporation To Report First Quarter 2019 Financial Results Before The Market Opens On Wednesday, May 1, 2019
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 1, 2019.
Apr 17, 2019 10:52 pm ET
United Therapeutics Issues Statement In Response To Meritless Lawsuit
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 17, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc. and RareGen, LLC on April 16, 2019. The lawsuit alleges that United Therapeutics engaged in anticompetitive conduct in connection with plaintiffs' efforts to launch their generic version of Remodulin® (treprostinil) Injection. United Therapeutics issued the following statement in response to the lawsuit:
Apr 08, 2019 06:00 am ET
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 8, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event. Accordingly, United Therapeutics has decided to discontinue further esuberaprost development.
Apr 01, 2019 08:00 am ET
Report: Exploring Fundamental Drivers Behind Coeur Mining, Owens & Minor, Telenav, Cedar Realty Trust, j2 Global, and United Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Coeur Mining, Inc. (NYSE:CDE), Owens & Minor, Inc. (NYSE:OMI), Telenav,...
Mar 12, 2019 06:00 am ET
United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 12, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 29th Annual Healthcare Conference in New York City.
Mar 04, 2019 05:00 am ET
United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 4, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.
Feb 27, 2019 05:00 am ET
United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2018.
Feb 20, 2019 05:00 am ET
United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and annual 2018 financial results before the market opens on Wednesday, February 27, 2019.
Jan 31, 2019 07:00 pm ET
Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that key data from the FREEDOM-EV study of Orenitram® (treprostinil) extended-release tablets were shared during an oral presentation at the Pulmonary Vascular Research Institute Annual World Congress on Pulmonary Vascular Disease in Barcelona, Spain. The presentation was given by R. James White, M.D., Ph.D., Professor of Medicine, Pharmacology & Physiology in the Division of Pulmonary & Critical Care Medicine at the University of Rochester
Jan 28, 2019 07:45 am ET
Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcomin
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Realty Income Corporation (NYSE:O), United Therapeutics Corporation...
Jan 24, 2019 07:00 pm ET
Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
SAN DIEGO, Jan. 24, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH).  The global license agreement for ralinepag was announced on November 15, 2018.
Jan 24, 2019 07:00 pm ET
United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag
RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).  Upon closing, United Therapeutics paid Arena
Dec 31, 2018 05:00 am ET
United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Dec 03, 2018 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR
NEW YORK, Dec. 3, 2018 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).  
Dec 03, 2018 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR
NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).  
Nov 29, 2018 03:30 pm ET
Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2018 /CNW/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Unituxin was previously approved by the U.S. Food and Drug Administration in March 2015.
Nov 29, 2018 03:30 pm ET
Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Unituxin was previously approved by the U.S. Food and Drug Administration in March 201
Nov 23, 2018 07:25 am ET
Report: Exploring Fundamental Drivers Behind Harvard Bioscience, TTM Technologies, BSQUARE, United Therapeutics, KCAP Financial, and Gladstone Capital — New Horizons, Emerging Trends, and Upcoming Dev
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Harvard Bioscience, Inc. (NASDAQ:HBIO), TTM Technologies, Inc....
Nov 15, 2018 06:00 am ET
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and United Therapeutics Corporation (Nasdaq: UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).
Nov 01, 2018 06:00 am ET
Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Nilda Mesa to its Board of Directors as an independent director. The appointment is effective as of October 31, 2018.
Oct 31, 2018 06:00 am ET
United Therapeutics Corporation Reports Third Quarter 2018 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended September 30, 2018.
Oct 24, 2018 06:00 am ET
United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018.
Oct 22, 2018 04:00 am ET
CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
NESS ZIONA, Israel and SILVER SPRING, Md., Oct. 22, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN, TASE: CLGN) and United Therapeutics Corporation (NASDAQ:UTHR) today announced that they have entered into a license, development and commercialization agreement for 3D bioprinted lung transplants. The agreement combines CollPlant's proprietary recombinant human collagen (rhCollagen) and BioInk technology with the regenerative medicine and organ manufacturing capabilities of United Therapeutics.
Oct 16, 2018 06:00 am ET
United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period
Oct 16, 2018 06:00 am ET
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil...
Sep 18, 2018 06:00 am ET
United Therapeutics Corporation To Host Science Day 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will host Science Day 2018 in New York City on Monday, September 24th, beginning at approximately 10:00 A.M. Eastern Time and ending at approximately 4:00 P.M. Eastern Time.
Sep 17, 2018 06:00 am ET
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
SAN DIEGO and SILVER SPRING, Md., Sept. 17, 2018 /PRNewswire/ -- Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF). Deal terms include $10 million up-front, plus up to $340 million in developmental milestones and up to low double-digit royalties.
Sep 04, 2018 06:00 am ET
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif., Sept. 4, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.
Sep 04, 2018 06:00 am ET
United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products
United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder...
Aug 30, 2018 07:08 am ET
United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.
SILVER SPRING, Md., Aug. 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) ("United Therapeutics") today announced that it has closed the merger of SteadyMed Ltd. (NASDAQ: STDY) ("SteadyMed") with a subsidiary of United Therapeutics. Pursuant to the merger, United Therapeutics acquired all of the outstanding ordinary shares of SteadyMed. As a result of the merger, SteadyMed ordinary shares are no longer publicly traded on the NASDAQ Stock Market.
Aug 08, 2018 08:00 pm ET
United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Watson Laboratories, Inc. ("Watson") resolving ongoing litigation concerning certain patents relating to United Therapeutics' product, Tyvaso® (treprostinil) Inhalation Solution, and Watson's Abbreviated New Drug Application ("ANDA") seeking approval by the U.S. Food and Drug Administration to market a generic version of Tyvaso.
Aug 08, 2018 06:00 am ET
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram® (treprostinil) extended-release tablets in patients suffering from pulmonary arterial hypertension (PAH) has met its primary endpoint of delayed time to first clinical worsening event.
Aug 07, 2018 04:00 pm ET
United Therapeutics Corporation To Present At 2018 Wedbush PacGrow Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 7, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the 2018 Wedbush PacGrow Healthcare Conference in New York City.
Aug 01, 2018 06:00 am ET
United Therapeutics Corporation Reports Second Quarter 2018 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 1, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2018.
Jul 31, 2018 06:00 am ET
SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics
SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that SteadyMed shareholders voted...
Jul 31, 2018 06:00 am ET
United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the Implantable System for Remodulin® (ISR).
Jul 26, 2018 06:00 am ET
United Therapeutics Corporation To Report Second Quarter 2018 Financial Results Before The Market Opens On Wednesday, August 1, 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 26, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its second quarter 2018 financial results before the market opens on Wednesday, August 1, 2018.
Jul 20, 2018 06:00 am ET
HSR Act Waiting Period Terminated for United Therapeutics' Acquisition of SteadyMed Ltd.
SILVER SPRING, Md. and SAN RAMON, Calif., July 20, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") relating to United Therapeutics' previously announced acquisition of SteadyMed.
Jul 20, 2018 06:00 am ET
HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd.
United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ:STDY) announced today the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) relating to United Therapeutics’...
Jun 25, 2018 07:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Dr Pepper Snapple Group, United Therapeutics, Universal Health Realty Income Trust, Forestar Group, Schlumberger, and Thermo Fisher
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dr Pepper Snapple Group, Inc. (NYSE:DPS), United Therapeutics Corporation...
Jun 12, 2018 01:30 am ET
United Therapeutics And XVIVO Perfusion Announce Collaboration To Reduce Organ Shortage Through Expansion Of Organ Evaluation Service
SILVER SPRING, Md. and ENGLEWOOD, Colo., June 12, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), today announced that the use of XVIVO's ex-vivo lung perfusion (EVLP) technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics' public benefit corporation subsidiary Lung Biotechnology PBC.
May 15, 2018 08:00 am ET
SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its...
May 04, 2018 07:50 am ET
Report: Exploring Fundamental Drivers Behind Reliance Steel & Aluminum, Goldman Sachs BDC, IBERIABANK, Federal Signal, United Therapeutics, and LifePoint Health — New Horizons, Emerging Trends, and Up
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Reliance Steel Aluminum Co. (NYSE:RS), Goldman Sachs BDC, Inc....
May 02, 2018 06:00 am ET
United Therapeutics Corporation Reports First Quarter 2018 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 2, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2018.
Apr 30, 2018 06:00 am ET
United Therapeutics To Acquire SteadyMed Ltd.
SILVER SPRING, Md. and SAN RAMON, Calif., April 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.
Apr 30, 2018 06:00 am ET
United Therapeutics to Acquire SteadyMed Ltd.
SILVER SPRING, Md. and SAN RAMON, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ:STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for...
Apr 24, 2018 06:00 am ET
United Therapeutics Corporation To Report First Quarter 2018 Financial Results Before The Market Opens On Wednesday, May 2, 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its first quarter 2018 financial results before the market opens on Wednesday, May 2, 2018.
Mar 21, 2018 07:55 am ET
Investor Expectations to Drive Momentum within JELD-WEN Holding, Nathan's Famous, Aerie Pharmaceuticals, RBC Bearings, Malibu Boats, and United Therapeutics — Discovering Underlying Factors of Influen
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of JELD-WEN Holding, Inc. (NYSE:JELD), Nathan's Famous,...
Mar 14, 2018 06:00 am ET
United Therapeutics Corporation To Present At Oppenheimer 28th Annual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 14, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 28th Annual Healthcare Conference in New York City.
Mar 07, 2018 05:00 am ET
United Therapeutics Corporation To Present At Cowen And Company 38th Annual Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 7, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Cowen and Company 38th Annual Health Care Conference in Boston, Massachusetts.
Feb 26, 2018 09:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of United Therapeutics Corporation (UTHR)
NEW YORK, Feb. 26, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/uthr.
Feb 24, 2018 12:00 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against United Therapeutics Corporation - UTHR
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of United Therapeutics Corporation (NASDAQ: UTHR) resulting from allegations that United Therapeutics may have issued materially misleading business information to the investing public.
Feb 21, 2018 11:07 am ET
Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its Shareholders
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at United Therapeutics Corporation (“United Therapeutics” or the “Company”) (NASDAQ:UTHR).
Feb 21, 2018 06:50 am ET
United Therapeutics Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / United Therapeutics Corporation (NASDAQ: UTHR) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at 9:00 AM Eastern Time.
Feb 21, 2018 05:00 am ET
United Therapeutics Corporation Reports 2017 Fourth Quarter And Annual Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2017.
Feb 15, 2018 07:00 pm ET
United Therapeutics Announces Settlement Of Patent Litigation With Actavis Laboratories FL, Inc. Relating To Orenitram
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Actavis Laboratories FL, Inc. ("Actavis") resolving ongoing litigation concerning certain patents relating to United Therapeutics' product, Orenitram® (treprostinil) Extended-Release Tablets, and Actavis' Abbreviated New Drug Application ("ANDA") seeking approval by the U.S. Food and Drug Administration to market a generic version of Orenitram.
Feb 15, 2018 11:00 am ET
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration
WARREN, N.J., Feb. 15, 2018 /PRNewswire/ -- Celularity has been created through the contribution and acquisition of extensive intellectual property, clinical-stage assets, basic and clinical research, and product development expertise including:
Feb 14, 2018 05:00 am ET
United Therapeutics Corporation To Report Fourth Quarter And Annual 2017 Financial Results Before The Market Opens On Wednesday, February 21, 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its fourth quarter and annual 2017 financial results before the market opens on Wednesday, February 21, 2018.
Jan 18, 2018 08:01 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within United Therapeutics, LTC Properties, WageWorks, Clearwater Paper, United Insurance, and CONMED — New Research Emphasizes Economic Gr
NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United Therapeutics Corporation (NASDAQ:UTHR), LTC Properties,...
Jan 17, 2018 03:02 pm ET
Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its Shareholders
NEW YORK, Jan. 17, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).
Jan 03, 2018 05:00 am ET
Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
SOUTH SAN FRANCISCO, Calif. and SILVER SPRING, Md., Jan. 3, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR), a leading biotechnology company focused on development of therapies for the treatment of pulmonary arterial hypertension (PAH), and Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced that they entered into an exclusive license agreement for Corsair's portfolio of patents covering treprostinil prodrugs as well as an equity investment by United Therapeutics in Corsair.
Dec 28, 2017 05:00 am ET
United Therapeutics Corporation To Present At 36th Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Nov 20, 2017 06:00 am ET
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca®
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Adcirca® (tadalafil) tablets through May 21, 2018, based on study results submitted by Eli Lilly and Company (Lilly) in response to a written request by the FDA to investigate the use of tadalafil in pediatric patients with Duchenne muscular dystrophy.
Nov 14, 2017 09:56 am ET
SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal Circuit
Court upholds USPTO ruling on U.S. Patent No. 8,497,393 against United Therapeutics
Oct 25, 2017 07:00 am ET
United Therapeutics Corporation Reports Third Quarter 2017 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 25, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2017.
Oct 23, 2017 07:00 am ET
United Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso® Inhalation System
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a new inhalation device, called the TD-300/A, for use with Tyvaso® (treprostinil) Inhalation Solution (Tyvaso).
Oct 19, 2017 07:00 am ET
United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On Wednesday, October 25, 2017
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2017 financial results before the market opens on Wednesday, October 25, 2017.
Sep 19, 2017 10:00 am ET
Martine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2017 /PRNewswire/ -- Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics Corporation (NASDAQ: UTHR) is featured in Forbes magazine's special centennial issue, released today, as one of The World's 100 Greatest Living Business Minds. In celebration of its 100th anniversary, Forbes magazine's collector's edition features essays, lessons and ideas for the next 100 years from today's most influential business leaders around the world. 
Sep 07, 2017 09:00 pm ET
United Therapeutics Announces FREEDOM-EV Study Of Orenitram® To Continue As Planned Following Interim Analysis
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 7, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the independent data monitoring committee (DMC) for the FREEDOM-EV study of Orenitram (treprostinil) extended-release tablets had completed a pre-specified interim safety and efficacy analysis. The DMC did not identify any new safety concerns associated with Orenitram therapy, and recommended that the trial be continued as planned without modification.
Aug 21, 2017 05:22 pm ET
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform
---New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration
Aug 21, 2017 05:22 pm ET
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform
---New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration
Aug 09, 2017 07:00 am ET
United Therapeutics Corporation To Present At 2017 Wedbush PacGrow Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 9, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 2017 Wedbush PacGrow Healthcare Conference in New York City.
Jul 28, 2017 11:09 am ET
Harwood Feffer LLP Announces Investigation of United Therapeutics Corporation
NEW YORK, July 28, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ:UTHR), concerning whether the board has breached its fiduciary duties to shareholders.
Jul 27, 2017 07:52 pm ET
UNITED THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In United Therapeutics Corporation To Contact The Firm
NEW YORK, July 27, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at United Therapeutics Corporation ("United Therapeutics" or the "Company") (NasdaqGS: UTHR).
Jul 27, 2017 05:36 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of United Therapeutics Corporation (UTHR)
NEW YORK, July 27, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/uthr.
Jul 27, 2017 07:00 am ET
United Therapeutics Corporation Reports Second Quarter 2017 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 27, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2017.
Jul 21, 2017 01:30 pm ET
United Therapeutics Corporation to Report Second Quarter 2017 Financial Results Before The Market Opens on Thursday, July 27, 2017
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 21, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its second quarter 2017 financial results before the market opens on Thursday, July 27, 2017.
May 31, 2017 07:00 am ET
United Therapeutics Corporation To Present At Jefferies 2017 Global Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 31, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Jefferies 2017 Global Healthcare Conference in New York, New York.
Apr 27, 2017 09:00 pm ET
United Therapeutics Announces $250 Million Share Repurchase Program
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 27, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to $250 million of the company's common stock. This program will became effective immediately, and will remain open through December 31, 2017. Purchases may be made in the open market, accelerated share repurchases or in privately negotiated transactions from time to time as determined by United Therapeutics' management and in accordance with the requirements of the U.S. Securities and Ex

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.